Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study published online March 17 in Scientific Reports.
Yasuhiro Suzuki, from University of Tsukuba in Japan, and colleagues examined the association of SGLT2 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists with falls in patients with type 2 diabetes. The analysis included annual fall survey responses from 471 participants with a median age of 64 years during a median period of two years.
The researchers found that the overall fall incidence rate was 17.1 per 100 person-years. Fall history, SGLT2 inhibitor use, and age were independent fall predictors. For using SGLT2 inhibitors only or GLP-1 receptor agonists and SGLT2 inhibitors combined, odds of falling were heightened (odds ratios, 1.80 and 2.89, respectively). However, the association was not significant for GLP-1 receptor agonists only.
"SGLT2 inhibitor use was an independent risk factor for falls, while GLP-1 receptor agonists' effects were not statistically significant. However, the combined use of SGLT2 inhibitors and GLP-1 receptor agonists significantly increased the risk of falls," the authors write. "Therefore, it is important to consider this risk when prescribing these medications to people with type 2 diabetes."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Clinical Practice Guidelines Issued for Diabetes Distress
THURSDAY, Sept. 25, 2025 -- The first clinical practice guidelines on assessment and management of diabetes distress among adults were presented at the annual meeting of the...
Oral Semaglutide Effective for Weight Loss in Overweight or Obesity
THURSDAY, Sept. 25, 2025 -- Oral semaglutide (25 mg) is effective for weight loss in adults with overweight or obesity without diabetes, according to a study published online...
GLP-1 Receptor Agonists Improve Glycemic, Weight Outcomes in Children With T2D
TUESDAY, Sept. 23, 2025 -- In children and adolescents with type 2 diabetes (T2D) or obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic, weight, and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.